PAH

IPF/PAH


FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements


DEMOGRAPHICS

  • Year of Birth
  • Gender
  • Weight
  • Height
  • BMI
  • Ethnicity
  • Race
  • Patient State

DIAGNOSTIC INFORMATION

  • Diagnosis Date
  • ICD 10 Code
  • PAH Symptom Onset Date
  • Etiology

DISPENSE INFORMATION

  • NDC Dispense
  • NDC Product Name
  • Dispense Item Strength
  • Refill Number / Days Supplied
  • Shipment Date

INSURANCE INFORMATION

  • Insurance Type
  • Patient Assistance or Self Pay
  • Copay Amount
  • Out of Pocket Amount
  • Patient Assistance Amount

MEDICAL HISTORY

  • Smoking Status
  • Alcohol Status
  • Illicit Drug Use
  • O2 Therapy Status
  • Transplant Status

COMORBIDITIES

  • Atrial Fibrillation
  • Chronic Kidney Disease
  • Cirrhosis
  • Clinical Depression
  • Connective Tissue Disease
  • COPD
  • CVD/CTD/CAD
  • Diabetes
  • Emphysema
  • Heart Failure – Systolic / Diastolic
  • History of Amiodarone / Cordarone
  • History of Chemotherapy
  • History of Prolonged Use of Furadantin/ Nitrofurantoin/ Macrodantin
  • GERD
  • Hypertension
  • NASH
  • History of Deep Vein Thrombosis
  • History of Pulmonary Embolism
  • Lung Cancer/ Fibrosis
  • Obstructive Sleep Apnea
  • Renal Insufficiency
  • Thyroid Disease
  • Validated History of Asbestos Exposure
  • Valvular Heart Disease
  • Other Cancers
  • Other Liver Diseases

LABS

  • ANA Screen
  • Anti Centromere
  • Anti dsDNA
  • Anti Scl-70
  • Cyclic Citrullinated Peptide
  • RF Factor
  • ECHO
  • VQ Scan
  • White Blood Cells
  • Polymorphonuclear Leukocytes
  • Red Blood Cells
  • Hemoglobin
  • Hematocrit
  • Red Blood Cell Distribution
  • Platelets
  • Serum Creatinine
  • AST
  • ALT
  • eGFR

TESTS

  • Pulmonary Function Test (FEV1, FVC)
  • FEV1/FVC ratio score
  • Diffusing Capacity for Carbon Monoxide (DLCO)
  • Most Recent Walk Test
  • Supplemental Oxygen
  • Lowest SpO2 During Walk
  • Borg Dyspnea Score (Before/ After Walk)
  • Borg Fatigue Score (Before/ After Walk)
  • Thermodilution
  • Right Heart Catheterization Date
  • Distance Walked
  • Max HR During Walk (bpm)
  • Number of Rests
  • Total Rest Time
  • CT Scan
  • CPET
  • BNP
  • NT-proBNP
  • mRAP
  • mPAP
  • PCWP
  • LVEDP
  • Fick
  • Cardiac Index
  • Pulmonary Vascular Resistance
  • Heart Rate
  • RVSP

Scientific Steering Committee


  • Independent Committee to review, approve and author all publications
  • Collaborative approach to develop strategic publication strategy
  • Collaborative workflow, methodology and communication with Trio Analytics and Client
  • Ongoing conference calls and meetings throughout the year
  • Responsive to real-world issues and clinical questions from real-world evidence

Harrison Farber, MD

  • Chairman – IPF/PAH Steering Committee, Trio Health
  • Director, Pulmonary Hypertension Center at Boston Medical Center, Boston, MA
  • Professor of Medicine- Boston University School of Medicine

Murali Chakinala, MD

  • Professor of Medicine, Washington University School of Medicine, St. Louis, MO
  • Director, Pulmonary Hypertension Center, Washington University, St. Louis, MO

Steven Nathan, MD

  • Professor of Medicine at Virginia Commonwealth University
  • Director of the Advanced Lung Disease Program at Inova Fairfax Hospital
  • Director of the Lung Transplant Program at Inova Fairfax Hospital

Robert Frantz, MD

  • Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
  • Director, Pulmonary Hypertension Clinic, Mayo Clinic

Adaani Frost, MD

  • Professor of Medicine, Institute of Academic Medicine, Houston Methodist
  • Former Medical Director of Lung Transplantation – Houston Methodist and developed both PF and IPF centers at the institution

Ronald Oudiz, MD

  • Professor of Medicine, David Geffen School of Medicine – UCLA
  • Director, Liu Center for Pulmonary Hypertension, LA BioMed Research Institute at Harbor – UCLA Medical Center

Lisa Lancaster, MD

  • Associate Professor of Medicine, Vanderbilt University, Nashville, TN
  • Clinical Director, Interstitial Lung Disease Program

Publications


2020